For decades, Alzheimer’s disease (AD) research has been dominated by the amyloid cascade hypothesis, which positions amyloid-beta (Aβ) accumulation as the primary driver of the disease. However, the consistent failure of Aβ-targeted therapies to demonstrate efficacy, coupled with significant safety concerns, has underscored the critical need to rethink our approach to AD treatment.

In our latest comprehensive review published in Microorganisms, led by Dr. Anna Onisiforou, we challenge this traditional perspective by exploring an emerging paradigm: the role of microbial factors in AD pathogenesis. Our analysis synthesizes mounting evidence suggesting that microbial infections may serve as crucial environmental factors in AD pathoetiology, examining the complex interactions between the gut microbiome, oral bacteria, brain biofilms, and viral infections in disease development and progression.

While a definitive causal link remains to be established, the collective evidence presents a compelling case for shifting our focus beyond the conventional amyloid hypothesis. This review not only highlights the potential mechanisms through which various microbial communities might influence AD pathogenesis but also explores promising microbiome-based therapeutic approaches that could revolutionize AD treatment strategies.

Read the full article at:
https://www.mdpi.com/2076-2607/13/1/90